Article Details
Retrieved on: 2024-02-05 00:33:52
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Bioxyne's Breathe Life Sciences division securing a TGA GMP license for manufacturing medical cannabis, MDMA, and psilocybin. It highlights the scope of the license and plans for exporting in 2024, contributing to the medical cannabis and pharmaceutical policy discussions.
Article found on: themarketonline.com.au
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here